Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640914 | 0.91 | TGFBR1 (0.46) | MAPK14TGFBR1MAPK11MAPK13MAPK12 | |
| SCHEMBL12727176 | 0.86 | TGFBR1 (0.51) | MAPK14TGFBR1EGFR | |
| SCHEMBL1905858 | 0.82 | USP2 (0.39) | MAPK14EGFR | |
| SCHEMBL6953086 | 0.82 | MAPK14 (0.64) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL7942534 | 0.82 | MAPK14 (0.50) | MAPK14TGFBR1 | |
| SCHEMBL1640318 | 0.79 | TGFBR1 (0.58) | MAPK14TGFBR1MAPK11MAPK13MAPK12 | |
| SCHEMBL7950070 | 0.79 | MAPK14 (0.58) | MAPK14CSNK1DCSNK1EEGFR | |
| SCHEMBL1639982 | 0.77 | MAPK14 (0.52) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL1640716 | 0.76 | MAPK14 (0.72) | MAPK14MAPK11MAPK13MAPK12CSNK1D | |
| SCHEMBL7950076 | 0.75 | MAPK14 (0.56) | MAPK14TGFBR1MAPK11MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493876-B1 | IMIDAZOLE DERIVATIVES AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8518944-B2 | Compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | CSNK1A1, CSNK1A1L, CSNK1G1 | MAPK14 169/4885TGFBR1 3920/4885MAPK11 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.